Kura Oncology, Inc. (KURA) intrinsic value & 10-year financials
Kura Oncology, Inc. (KURA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 25.2% a year to $67.5M, with an average return on invested capital of -65.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $9.08
- Market cap
- $796.1M
- Revenue (FY2025)
- $67.5M
- Revenue growth (10-yr CAGR)
- 25.2%
- ROIC (10-yr avg)
- -65.7%
- Free cash flow (FY2025)
- -$70.7M
KURA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $67.5M | -$278.7M | -$3.18 | -$70.7M | -449.9% | -244.8% |
| FY2024 | $53.9M | -$174.0M | -$2.02 | $133.8M | -358.5% | -66.7% |
| FY2023 | $0 | -$152.6M | -$2.08 | -$125.0M | — | -43.9% |
| FY2022 | — | -$135.8M | -$2.03 | -$110.7M | — | -34.9% |
| FY2021 | — | -$130.5M | -$1.97 | -$105.7M | — | -36.3% |
| FY2020 | — | -$89.6M | -$1.69 | -$72.0M | — | -36.0% |
| FY2019 | — | -$63.1M | — | — | — | -35.8% |
| FY2018 | — | -$60.4M | — | — | — | -53.0% |
| FY2017 | — | -$35.4M | — | — | — | -54.5% |
| FY2016 | — | -$27.6M | — | — | — | -50.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Kura Oncology, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Kura Oncology, Inc. has historically struggled to out-earn its cost of capital, averaging just -41.4% ROIC.
Kura Oncology, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Kura Oncology, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-105.63 per share.